Walleye Capital’s Cue Biopharma CUE Stock Holding History

Walleye Capital’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,309	Closed	-$192K	–	2429
2022 Q1	$192K	Buy	+1,309	New	+$278K	0.01%	1537

Other funds holding CUE

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Walleye Capital's CUE Position: Q2 2022 in Review

Walleye Capital sold out of Cue Biopharma (CUE) in Q2 2022, closing a stake of 1,309 shares — an estimated $192K sold.

Walleye Capital first reported a position in CUE in Q1 2022 and held it in 1 quarter. The position peaked at $192K in Q1 2022. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2022.

Walleye Capital reported no remaining Cue Biopharma position as of Q2 2022 after selling out during the quarter.
Walleye Capital sold 1,309 Cue Biopharma shares in Q2 2022, an estimated $192K.
Walleye Capital first reported a position in Cue Biopharma in Q1 2022 and held it in 1 quarter.
Walleye Capital's Cue Biopharma position peaked at $192K in Q1 2022.
75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2022.

Based on Walleye Capital's 13F filing for Q2 2022, filed 8 Aug 2022.